- Clinical Significance and Natural History of "HBeAg Negativity" in Patients with Chronic HBV Infection
-
Lee YS
- KMID: 760639
- Korean J Hepatol.
- 2006 Jun;12(2):133-135.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- HBV DNA Levels, Aminotransferase and Histological Activity in Young Male Patients with HBeAg Positive Chronic Hepatitis B
-
Cho SC, Lee SH, Shinn JJ, Han SH, Roh BJ, Sohn JH, Lee DH, Kee CS
- KMID: 863067
- Korean J Hepatol.
- 2002 Mar;8(1):44-51.
BACKGROUND/AIM: A significant correlation between HBV DNA and liver damage was found in precore mutant strains but there was no significant association between viral replication and liver damage in HBeAg... -
- CITED
-
- Close
- SHARE
-
- Close
- Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
-
Song BC, Cho YK, Jwa H, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU
- KMID: 2070253
- Clin Mol Hepatol.
- 2014 Dec;20(4):355-360.
- doi: 10.3350/cmh.2014.20.4.355
BACKGROUND/AIMS: Spontaneous HBeAg seroconversion occurs frequently in the immune reactive phase in HBeAg-positive chronic hepatitis B (CHB). Therefore, observation for 3-6 months before commencing antiviral therapy is recommended in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum ALT and HBV DNA Levels in Patients with HBeAg-Negative Chronic Hepatitis B
-
Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, Song CS, Heo J, Cho M
- KMID: 1085301
- Korean J Hepatol.
- 2003 Dec;9(4):284-292.
BACKGROUND/AIMS: HBeAg-negative chronic hepatitis B (CHB) has a poor long-term prognosis. Since no precise clinically relevant HBV thresholds are known in HBeAg-negative CHB, the decision to treat is difficult.... -
- CITED
-
- Close
- SHARE
-
- Close
- Natural History of HBeAg Negative Chronic Hepatitis B Virus Infection: A Cohort Study
-
Moon CM, Kim DY, Song KJ, Kim JK, Lee HW, Lee JM, Yoon KT, Paik YH, Kim DK, Han KH, Chon CY, Moon YM, Ahn SH
- KMID: 760643
- Korean J Hepatol.
- 2006 Jun;12(2):163-172.
BACKGROUND/AIMS: The long-term virologic and biochemical changes in patients with HBeAg negative HBV infection, especially in Asia, remain unclear. To address this issue, we conducted a 3 year- retrospective,... -
- CITED
-
- Close
- SHARE
-
- Close
- Pretreatment ALT Level and Histologic Activity as Predictors of HBeAg Loss in Lamivudine Treatment for Chronic Hepatitis B
-
Kweon YO, Kang KH
- KMID: 760529
- Korean J Hepatol.
- 2004 Mar;10(1):31-41.
BACKGROUND/AIMS: Lamivudine is a potent inhibitor of hepatitis B virus replication, but an increased incidence of YMDD mutation may be associated with its long term use. Thus, the decision... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naive Patients with HBeAg Positive Chronic Hepatitis B
-
Kim IH, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Choi CS, Kim HC
- KMID: 1713959
- J Korean Med Sci.
- 2010 May;25(5):738-745.
- doi: 10.3346/jkms.2010.25.5.738
The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naive patients with HBeAg positive chronic hepatitis B. In this retrospective study, a... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B
-
Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ
- KMID: 2373390
- Korean J Gastroenterol.
- 2016 Jan;67(1):28-34.
- doi: 10.4166/kjg.2016.67.1.28
BACKGROUND/AIMS: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after... -
- CITED
-
- Close
- SHARE
-
- Close
- Viral Breakthrough in HBeAg-Negative Chronic Hepatitis B Patients Receiving Lamivudine Therapy
-
Chang YJ, Yim JY, Cho NY, Choi CW, Baek SJ, Ahn SH, Choi DW, Kwon YD, Kim SS, Kwon OS, Kim JH, Yeon JE, Song JW, Byun KS, Lee CH
- KMID: 863115
- Korean J Hepatol.
- 2002 Dec;8(4):397-404.
BACKGROUND/AIMS: Long-term efficacy and the rate of viral breakthrough in patients with HBeAg- negative chronic hepatitis B receiving lamivudine therapy is uncertain. This study was conducted to determine the... -
- CITED
-
- Close
- SHARE
-
- Close
- Change of HBV DNA Level as a Predictor of HBeAg Loss after Lamivudine Treatment
-
Jung JK, Lee CH, Kim EY, Jung JT, Choi JH, Han JM, Jin MI, Cho JY, Kim BS, Shin IH
- KMID: 1776827
- Korean J Hepatol.
- 2007 Dec;13(4):513-520.
- doi: 10.3350/kjhep.2007.13.4.513
BACKGROUND AND AIMS: Lamivudine is an effective, safe therapeutic agent for the treatment of chronic hepatitis B. The aim of this study was to investigate whether early suppression of... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Efficacy of Clevudine, Entecavir and Lamivudine in Treatment-naive Patients with HBeAg-Positive Chronic Hepatitis B
-
Bae SH, Baek YH, Lee SW, Han SY
- KMID: 1775852
- Korean J Gastroenterol.
- 2010 Dec;56(6):365-372.
- doi: 10.4166/kjg.2010.56.6.365
BACKGROUND/AIMS: Clevudine is a potent antiviral agent that has demonstrated efficacy in patients with chronic hepatitis B. This study compared the efficacy of clevudine (C), entecavir (E) and lamivudine (L)... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Lamivudine in Patients with Hepatitis B e Antigen-Negative Chronic Liver Diseases
-
Jeong ID, Park NH, Kim BC, Park JH, Seo KW, Kim DH, Joo KR, Kim DH
- KMID: 863140
- Korean J Hepatol.
- 2003 Jun;9(2):69-78.
BACKGROUND/AIMS: Lamivudine therapy is effective in inhibiting HBV replications in patients with HBeAg-negative chronic liver disease. However, the sustained response rate appears to be particularly poor, because the vast... -
- CITED
-
- Close
- SHARE
-
- Close
- Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients
-
Jung HW, Choi MS, Kim KH, Park SH, Yeon KK, Lee JH, Koh KC, Paik SW, Yoo BC
- KMID: 1776814
- Korean J Hepatol.
- 2009 Mar;15(1):52-58.
- doi: 10.3350/kjhep.2009.15.1.52
BACKGROUNDS/AIMS: It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection,... -
- CITED
-
- Close
- SHARE
-
- Close
- HBV-specific CD8+ T cells for Sustained HBeAg Seroconversion after Lamivudine Therapy
-
Lee CK, Han KH, Suh JH, Cho YS, Won SY, Chon CY, Moon YM, Park IS
- KMID: 760578
- Korean J Hepatol.
- 2005 Mar;11(1):34-42.
BACKGROUND/AIMS: Viral suppression of the hepatitis B virus (HBV) can be induced by lamivudine, but the relapse seen in many patients after cessation of lamivudine therapy is troublesome. We... -
- CITED
-
- Close
- SHARE
-
- Close
